Theravance Biopharma (NASDAQ:TBPH) Rating Lowered to Buy at Wall Street Zen

Theravance Biopharma (NASDAQ:TBPH) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

TBPH has been the topic of a number of other research reports. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. B. Riley initiated coverage on Theravance Biopharma in a report on Friday, September 12th. They set a “buy” rating and a $28.00 price target on the stock. HC Wainwright increased their price target on Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. BTIG Research boosted their price objective on Theravance Biopharma from $25.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, November 26th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $27.80.

Theravance Biopharma Stock Performance

NASDAQ TBPH opened at $18.15 on Friday. The firm has a 50 day simple moving average of $17.63 and a 200-day simple moving average of $14.43. Theravance Biopharma has a one year low of $7.90 and a one year high of $20.33. The firm has a market cap of $919.66 million, a price-to-earnings ratio of 31.84 and a beta of 0.14.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.10. The firm had revenue of $19.99 million for the quarter, compared to the consensus estimate of $19.89 million. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. Equities analysts predict that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total transaction of $582,506.25. Following the sale, the senior vice president owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. This trade represents a 10.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds have recently added to or reduced their stakes in the stock. Quarry LP purchased a new stake in shares of Theravance Biopharma during the third quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd raised its position in Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,411 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares during the period. CIBC Private Wealth Group LLC boosted its holdings in shares of Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 4,662 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Theravance Biopharma during the third quarter worth about $101,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.